Core Viewpoint - The recent approval of oral semaglutide, a GLP-1 class drug, by the FDA for weight management has reignited public interest in easier weight loss methods [6] Mechanism of Action - Semaglutide does not directly burn fat; instead, it acts as a GLP-1 analog that regulates blood sugar and energy metabolism by promoting insulin secretion, inhibiting glucagon release, and delaying gastric emptying, which reduces hunger and food intake [8] - The oral formulation requires higher doses due to lower absorption efficiency in the gastrointestinal tract and has strict administration requirements, such as taking it on an empty stomach with minimal water [8] Clinical Indications - Current weight loss prescription drugs in China primarily consist of GLP-1 class medications, suitable for individuals with a BMI ≥ 28 or BMI ≥ 24 with obesity-related conditions [9] - The only over-the-counter weight loss drug available is orlistat, which has notable tolerance and side effect issues [9] - New-generation weight loss drugs targeting multiple pathways show potential but require ongoing observation for long-term safety and tolerance [9] Risks and Management - The emergence of oral formulations raises concerns about drug misuse, particularly among individuals with normal weight seeking rapid weight loss, which can lead to adverse health effects [9] - Weight management should not solely rely on medication; lifestyle changes such as dietary adjustments, regular exercise, and adequate sleep are essential for sustainable weight control [10] Sustainable Weight Management - The focus of weight loss should extend beyond just reducing numbers on the scale to preserving muscle mass and maintaining metabolic health through adequate protein intake and resistance training [10] - Any medication use should be under medical supervision, with a clear strategy for weight maintenance post-medication [10]

Core Insights - Obesity is a chronic and relapsing disease affecting nearly 2 billion adults globally, increasing the risk of other chronic diseases and premature death [1][9] - The emergence of GLP-1 receptor agonists and GLP-1/GIP dual agonists is seen as a transformative approach to obesity treatment, offering significant weight loss and cardiovascular protection [1][9] - A recent systematic review and meta-analysis published in the BMJ highlights the common issue of weight regain after cessation of these medications, emphasizing the need for understanding this rebound for long-term management [9][14] Study Overview - The analysis included 37 studies with 9,341 participants and an average follow-up of 32 weeks, focusing on weight management medications compared to non-pharmacological interventions or placebos [9][10] - Among the studies, 35 were randomized controlled trials, but only 28 had control groups during both intervention and follow-up periods [10] Weight Loss and Rebound - The average weight loss during treatment across all medication groups was 8.3 kg, compared to 3.2 kg in control groups [11] - GLP-1 receptor agonists achieved an average weight loss of 10.1 kg, while newer agents like semaglutide and tirzepatide reached 14.7 kg [11] - Post-medication, the average weight regain rate was 0.4 kg/month, with a return to baseline weight expected in 1.7 years [11][14] Cardiovascular and Metabolic Indicators - During treatment, HbA1c decreased by 0.9 mmol/mol, with a monthly increase of 0.05 mmol/mol post-treatment [13] - Other indicators such as fasting blood glucose, systolic blood pressure, and cholesterol levels also showed significant reductions during treatment, but began to rise again after cessation [13] Comparison with Behavioral Interventions - Behavioral interventions resulted in an average weight loss of 5.1 kg, with a slower rebound rate of 0.1 kg/month, taking approximately 3.9 years to return to baseline [7][14] - Sensitivity analyses indicated that the rebound rate for medication groups was consistently faster than for behavioral interventions, regardless of initial weight loss [7][14] Conclusion and Future Directions - The findings suggest that while weight loss medications are effective, their benefits diminish after discontinuation, necessitating long-term management strategies [14] - The commentary accompanying the study stresses that GLP-1 receptor agonists should not be viewed as a "magic bullet" for obesity, highlighting the importance of a healthy diet and lifestyle as foundational elements of obesity management [14]

Core Viewpoint - The article discusses the recent approval of oral semaglutide, a GLP-1 class drug, by the FDA for weight management, highlighting its potential to simplify weight loss efforts while emphasizing that weight loss is not merely about taking a pill [6]. Mechanism of Action - Semaglutide works by activating GLP-1 receptors, promoting insulin secretion, inhibiting glucagon release, and delaying gastric emptying, which collectively reduce hunger and food intake [8]. - The oral formulation requires higher doses due to lower absorption efficiency in the gastrointestinal tract and has specific administration requirements, such as taking it on an empty stomach [8]. Clinical Indications - Current weight loss prescription drugs in China primarily consist of GLP-1 medications, suitable for individuals with a BMI ≥ 28 or BMI ≥ 24 with obesity-related conditions [9]. - The only non-prescription weight loss drug available is orlistat, which has notable tolerance and side effect issues [9]. Emerging Weight Loss Drugs - New generation weight loss drugs targeting multiple pathways show promise for better weight control and metabolic improvement, but their long-term safety and tolerability need further observation [9]. - The emergence of oral formulations raises concerns about potential misuse among individuals not meeting the clinical indications, particularly those with normal weight seeking rapid weight loss [9]. Weight Management Strategy - Weight management should focus on preserving muscle mass and maintaining metabolic health, with adequate protein intake, resistance training, and good sleep being essential for sustainable weight management [10]. - Medications should be used under medical supervision, with a clear strategy for maintaining weight after discontinuation to avoid misconceptions about weight loss drugs as quick fixes [10].

Core Viewpoint - The oral version of semaglutide, a "star drug" for weight loss, has been approved by the U.S. FDA, following the approval of its injectable form as the world's first GLP-1 class weight loss medication, sparking public interest in convenient weight loss solutions [1] Group 1: Mechanism of Action - GLP-1 (glucagon-like peptide-1) regulates insulin and glucagon secretion based on blood sugar levels, and semaglutide is a similar compound that activates receptors in various cells to promote insulin secretion, suppress glucagon, and delay gastric emptying, thereby reducing appetite [2] - The core mechanism of semaglutide for weight loss is not fat burning but rather activating neural circuits related to satiety in the hypothalamus and brainstem, leading to reduced hunger and delayed feelings of hunger after meals [2] Group 2: Drug Comparison and Usage - The oral and injectable forms of semaglutide share the same active ingredients and mechanisms, with the oral form being more convenient but requiring higher doses due to lower bioavailability [3] - Current weight loss prescription drugs in China primarily consist of GLP-1 class medications, with BMI (Body Mass Index) being a key criterion for usage; individuals with a BMI of 28 or higher, or 24 with obesity-related complications, may be prescribed these medications [4] - Other weight loss medications include orlistat, which is the only over-the-counter option, but it has poor tolerance and more side effects; new generation dual-target and triple-target weight loss drugs are under development [4] Group 3: Risks of Misuse - The convenience of the oral version raises concerns about potential drug misuse, particularly among individuals not meeting the criteria for its use, which could lead to negative health outcomes such as muscle loss, nutritional deficiencies, and increased risks of gallstones and thyroid tumors [5] - Lifestyle interventions remain essential for effective weight management, and the public should not rely solely on medications for rapid weight loss, as there is a risk of rebound weight gain after discontinuation [6]

Core Viewpoint - The American College of Cardiology (ACC) has officially recognized semaglutide and tirzepatide as preferred medications for obesity treatment, marking a significant shift in the management of obesity and its associated cardiovascular risks [7][10]. Summary by Sections Breakthrough Therapies - Innovative drugs like semaglutide and tirzepatide not only significantly reduce weight but also provide additional cardiovascular protection for high-risk patients, particularly those with type 2 diabetes or existing cardiovascular diseases [10]. Obesity as a Health Threat - Obesity is highlighted as a serious health risk, leading to metabolic disorders, respiratory issues, and various heart diseases. It is recognized as an independent risk factor for cardiovascular diseases [11]. Weight Loss Thresholds - Different weight loss percentages yield varying cardiovascular benefits: a 10%-15% weight loss can reduce general cardiovascular risks, while heart failure patients may need to lose over 15% for significant improvement [12]. Treatment Options - The treatment landscape includes lifestyle interventions, weight loss surgery, and pharmacotherapy. The ACC suggests a reevaluation of the traditional approach of prioritizing lifestyle changes before medication [15]. Third-Generation Weight Loss Drugs - Semaglutide and tirzepatide represent a revolutionary choice in obesity management, with long-term efficacy and safety data supporting their use for weight loss [16]. Weight Loss Effectiveness - Comparative data shows that semaglutide leads to an average weight loss of 14.9%, while tirzepatide achieves an average of 20.9%, making it the most effective option currently available [18][20]. Long-Term Treatment Importance - Long-term treatment is crucial as stopping medication can lead to weight regain. Continuous use combined with lifestyle adjustments is essential for maintaining weight loss [21]. Accessibility and Economic Burden - The main challenges for semaglutide and tirzepatide include limited supply and high costs, which may affect patient access to these therapies [22]. Cardiovascular Benefits Beyond Weight Loss - The NuSH therapy not only aids in weight loss but also reduces the risk of heart attacks and strokes in obese patients without diabetes, and improves outcomes for heart failure patients [23]. Approved Weight Loss Medications in China - The 2024 guidelines in China have approved five medications for adult weight loss, emphasizing a multidisciplinary approach to obesity treatment [24].

Core Viewpoint - The article discusses a systematic review and network meta-analysis published in The Lancet, which evaluates the effectiveness and safety of seven weight loss medications for overweight and obese adults, highlighting that the combination of phentermine-topiramate and GLP-1 receptor agonists, particularly semaglutide, show the most significant weight loss effects [5][19]. Research Methodology - The research team systematically searched three major databases: PubMed, Embase, and Cochrane Library, including randomized controlled trials (RCTs) published until March 23, 2021, focusing on weight loss medications for overweight and obese adults [7]. - Exclusion criteria included studies with a crossover design, combination of multiple medications, participants with psychological disorders, pregnant women, normal weight individuals, and non-English publications [7]. Study Results - A total of 14,605 articles were screened, resulting in 132 studies included, with 48,209 participants. The median age of participants was 47 years, with a female proportion of 76% and a median BMI of 35.3 kg/m² [11]. - The study assessed the impact of seven medications on six outcome measures, including weight loss percentage, proportion of participants achieving 5% or 10% weight loss, quality of life improvement, reduction in depressive symptoms, and safety indicators [10]. Comparative Effectiveness - Compared to lifestyle modifications alone, all weight loss medications resulted in additional weight loss. Phentermine-topiramate showed the most significant weight loss effect, with an odds ratio (OR) of 8.02 for achieving a weight reduction of ≥5% and an average weight loss percentage of -7.98% [17]. - GLP-1 receptor agonists also demonstrated significant effects, with an OR of 6.33 for achieving a weight reduction of ≥5% and an average weight loss percentage of -5.79% [17]. Specific Drug Analysis - Among GLP-1 receptor agonists, semaglutide exhibited the most pronounced weight loss effects, with an OR of 9.82 for achieving a weight reduction of ≥5% and an average weight loss percentage of -11.40% [18]. - Safety data indicated that medications like naltrexone-bupropion, phentermine-topiramate, GLP-1 receptor agonists, and orlistat were associated with an increased risk of discontinuation due to adverse events [18]. Conclusion - The network meta-analysis provides high to moderate confidence evidence that phentermine-topiramate and GLP-1 receptor agonists, especially semaglutide, are the most effective weight loss medications, with average weight reductions ranging from 6% to 11% [19].

Core Viewpoint - The article discusses the rising obesity rates in China, highlighting the need for effective weight management strategies and the increasing popularity of specialized weight loss clinics that offer comprehensive treatment plans [5][12][20]. Group 1: Obesity Statistics and Causes - According to the National Health Commission, the overweight rate in China is 34.3% and the obesity rate is 16.4%, indicating that over 700 million people are facing weight issues [5]. - Factors contributing to obesity include lifestyle pressures, unregulated diets, and mental health challenges, leading to the emergence of various weight loss methods [5][12]. Group 2: Weight Management Clinics - The year has been designated as the "Weight Management Year," prompting a surge in young people visiting nutrition clinics for professional weight loss advice [5][12]. - Modern medical approaches provide tailored weight loss plans, including dietary recommendations, exercise suggestions, and, when necessary, medication or surgery [5][12]. Group 3: Patient Experiences - Case studies of individuals like Ouyang and Manxiao illustrate the emotional and physical struggles associated with obesity, as well as their journeys through weight loss clinics [7][15]. - Patients undergo comprehensive assessments, including questionnaires about eating habits and physical conditions, to receive personalized treatment plans [9][11]. Group 4: Treatment Approaches - The treatment strategies involve lifestyle interventions, such as dietary adjustments and exercise regimens, with some patients opting for medication like GLP-1 receptor agonists under medical supervision [20][22]. - The article emphasizes that obesity is a chronic disease requiring a systematic approach, including lifestyle changes, medication, and possibly surgical options for severe cases [15][20]. Group 5: Long-term Management - Patients are encouraged to view weight management as a lifelong commitment, focusing on sustainable lifestyle changes rather than quick fixes [24]. - The experiences shared highlight the importance of professional guidance in navigating the complexities of weight loss and maintaining a healthy lifestyle [24].

Core Viewpoint - The article discusses a systematic review and network meta-analysis published in The Lancet, which evaluates the weight loss effects and safety of seven medications for overweight and obese adults, highlighting that the combination of phentermine-topiramate and GLP-1 receptor agonists, particularly semaglutide, show the most significant weight loss potential [5][19]. Research Methodology - The research team systematically searched three major databases: PubMed, Embase, and Cochrane Library, including randomized controlled trials (RCTs) published until March 23, 2021, focusing on weight loss medications for overweight and obese adults [7]. - Exclusion criteria included studies with a crossover design, those using multiple medications, participants with psychological disorders, pregnant women, normal-weight individuals, and non-English publications [7]. Study Results - A total of 14,605 articles were screened, resulting in 132 studies included, with 48,209 participants. The median age of participants was 47 years, with a female proportion of 76% and a median BMI of 35.3 kg/m² [11]. - The study assessed the impact of seven medications on six outcome measures, including weight loss percentage, proportion of participants achieving 5% or 10% weight loss, quality of life improvement, reduction in depressive symptoms, and safety indicators [10]. Comparative Effectiveness - Compared to lifestyle modifications alone, all weight loss medications provided additional weight reduction. Phentermine-topiramate showed the most significant effect, with an odds ratio (OR) of 8.02 for achieving a weight loss of ≥5% and an average weight reduction of -7.98% [17]. - GLP-1 receptor agonists also demonstrated substantial effects, with an OR of 6.33 for achieving a weight loss of ≥5% and an average weight reduction of -5.79% [17]. Specific Drug Analysis - Among GLP-1 receptor agonists, semaglutide exhibited the most pronounced weight loss effects, with an OR of 9.82 for achieving a weight loss of ≥5% and an average weight reduction of -11.40% [18]. - Safety data indicated that medications like naltrexone-bupropion, phentermine-topiramate, GLP-1 receptor agonists, and orlistat were associated with an increased risk of discontinuation due to adverse events [18]. Conclusion - The network meta-analysis provides high to moderate confidence evidence that phentermine-topiramate and GLP-1 receptor agonists, especially semaglutide, are the most effective weight loss medications, with average weight reductions ranging from 6% to 11% [19].

Core Viewpoint - The article discusses the current landscape of weight loss medications in China, focusing on the differences between new-generation GLP-1 drugs and traditional weight loss medications, highlighting their mechanisms, efficacy, and safety profiles [4][7]. Group 1: Overview of Weight Loss Medications - There are six weight loss drugs currently approved in China, including three new-generation GLP-1 drugs: Semaglutide, Tirzepatide, and Mounjaro, and three traditional drugs: Benaglutide, Liraglutide, and Orlistat [4][7]. - New-generation GLP-1 drugs have longer action times and more significant weight loss effects compared to first-generation drugs [4][6]. Group 2: Mechanisms and Administration - The six weight loss drugs differ in their mechanisms of action and target populations, with new-generation drugs showing better safety and efficacy [7]. - All approved GLP-1 weight loss medications are currently available only as subcutaneous injections, with no oral versions available yet [6]. Group 3: Indications and Contraindications - Weight loss medications should be considered for patients who have not achieved a weight loss of at least 5% after three months of lifestyle intervention, even for those who are merely overweight without complications [9]. - A comprehensive assessment is necessary before starting medication, especially for high-risk populations such as the elderly or those with liver and kidney dysfunction [10]. Group 4: Clinical Application Process - Diagnosis of obesity or overweight should consider BMI, metabolic indicators, and related comorbidities, with obesity defined as BMI ≥ 28 kg/m² [12]. - The selection of medications should prioritize those with additional clinical benefits for patients with comorbid conditions like type 2 diabetes or cardiovascular diseases [13]. Group 5: Monitoring and Management - Regular monitoring of body composition and metabolic indicators is essential, with evaluations occurring monthly during the initial three months and quarterly thereafter [16]. - For elderly patients, careful consideration of muscle mass and potential drug interactions is crucial, with recommendations for dose adjustments based on renal and hepatic function [19].

Core Viewpoint - The American College of Cardiology (ACC) has officially recognized semaglutide and tirzepatide as preferred medications for obesity treatment, marking a significant shift in obesity management strategies [4][7]. Group 1: Breakthrough Therapies - Innovative drugs like semaglutide and tirzepatide not only significantly reduce weight but also provide additional cardiovascular protection for high-risk patients, effectively lowering the risks of cardiovascular death, heart attacks, and strokes [10]. - These medications represent the most effective weight loss solutions currently available, particularly for patients with type 2 diabetes or existing cardiovascular diseases [10]. Group 2: Obesity as a Health Threat - Obesity is highlighted as a critical health risk, contributing to metabolic disorders, respiratory issues, and various heart diseases, and is recognized as an independent risk factor for cardiovascular diseases [11]. - The consensus emphasizes that obesity is not merely an aesthetic issue but a serious health concern that requires urgent attention [11]. Group 3: Weight Loss Thresholds - Research indicates that different degrees of weight loss yield varying cardiovascular benefits: a 10%-15% weight loss can reduce general cardiovascular risks, while heart failure patients may need to lose over 15% for significant improvements [12]. - The treatment options include lifestyle interventions, weight loss surgery, and pharmacotherapy, with the latter being increasingly favored due to its effectiveness and safety [12][13]. Group 4: NuSH Therapy Advantages - NuSH therapy, which includes semaglutide and tirzepatide, is praised for its unique advantages, including targeting appetite regulation and allowing for personalized dosage adjustments to achieve optimal results [19]. - The therapy is seen as a pivotal advancement in obesity treatment, ushering in an era of precision medicine [13]. Group 5: Comparison of Weight Loss Medications - Semaglutide (weekly) leads to an average weight loss of 14.9%, while tirzepatide (weekly) shows the highest efficacy with an average weight loss of 20.9% [18][20]. - Other medications like liraglutide (daily) result in an average weight loss of 8% [18]. Group 6: Long-term Treatment and Challenges - Long-term treatment is crucial, as discontinuation can lead to weight regain; thus, a combination of medication and lifestyle changes is essential for maintaining weight loss [21]. - Current challenges include limited availability and high costs of semaglutide and tirzepatide, which may hinder accessibility for patients [22]. Group 7: Cardiovascular Benefits Beyond Weight Loss - The benefits of NuSH therapy extend beyond weight reduction, with semaglutide reducing the risk of heart attacks and strokes in non-diabetic obese patients, and improving exercise capacity in heart failure patients [23]. - Treatment goals should be individualized, focusing on weight loss of at least 5% to improve metabolic health and 10% for cardiovascular benefits [23].